Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: A randomized, 12-month, double-blind, placebo-controlled study

Arthritis Research and Therapy

Volumn 9, Issue 5, 2007, Pages

  Krzeski, Piotr ^a   Buckland Wright, Chris ^b   Bálint, Géza ^c   Cline, Gary A ^d   Stoner, Karen ^a   Lyon, Robert ^d   Beary, John ^d   Aronstein, William S ^d   Spector, Tim D ^e  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; LACTOSE; MAGNESIUM STEARATE; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PG 116800; PG 530742; SODIUM DERIVATIVE; UNCLASSIFIED DRUG; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; PG-116800; PROTEINASE INHIBITOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DUPUYTREN CONTRACTURE; FEMALE; FLUOROSCOPY; FOLLOW UP; FROZEN SHOULDER; FUNCTIONAL ASSESSMENT; HAND DISEASE; HAND EDEMA; HUMAN; JOINT FUNCTION; JOINT RADIOGRAPHY; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NECK PAIN; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; TENDON DISEASE; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXAMIC ACIDS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MUSCULOSKELETAL DISEASES; OSTEOARTHRITIS, KNEE; PROTEASE INHIBITORS;

EID: 36849020581     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2315     Document Type: Article

References (37)

1. Keuttner K Godberg VM (Eds) Osteoarthritic Disorders Rosemont, IL, USA: American Academy of Orthopaedic Surgeons 1995: 21-25
2. Oliveria SA Felson DT Reed JI Cirillo PA Walker AM Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization Arthritis Rheum 1995, 38:1134-1141 10.1002/art.1780380817 7639811
3. Coussens LM Fingleton B Matrisian LM Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 2002, 295:2387-2392 10.1126/ science.1067100 11923519
4. Chau I Rigg A Cunningham D Matrix metalloproteinase inhibitors - an emphasis on gastrointestinal malignancies Crit Rev Oncol Hematol 2003, 45:151-176 10.1016/S1040-8428(02)00015-X 12604127
5. Shaw T Nixon JS Bottomley KM Metalloproteinase inhibitors: New opportunities for the treatment of rheumatoid arthritis and osteoarthritis Expert Opin Investig Drugs 2000, 9:1469-1478 10.1517/ 13543784.9.7.1469 11060752
6. Bigg HF Rowan AD The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis Curr Opin Pharmacol 2001, 1:314-320 10.1016/S1471-4892(01)00055-8 11712757
7. Cawston TE Metalloproteinase inhibitors and the prevention of connective tissue breakdown Pharmacol Ther 1996, 70:163-182 10.1016/ 0163-7258(96)00015-0 8888065
8. Lohmander LS Hoerrner LA Lark MW Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis Arthritis Rheum 1993, 36:181-189 10.1002/art.1780360906 8431206
9. Janusz MJ Hookfin EB Heitmeyer SA Woessner JF Freemont AJ Hoyland JA Brown KK Hsieh LC Almstead NG De B Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors Osteoarthritis Cartilage 2001, 9:751-760 10.1053/ joca.2001.0472 11795995
10. Fujisawa T Igeta K Odake S Morita Y Yasuda J Morikawa T Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model Bioorg Med Chem 2002, 10:2569-2581 10.1016/S0968-0896(02)00109-8 12057646
11. Lewis EJ Bishop J Bottomley KM Bradshaw D Brewster M Broadhurst MJ Brown PA Budd JM Elliott L Greenham AK Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo Br J Pharmacol 1997, 121:540-546 10.1038/sj.bjp.0701150 9179398
12. Brewster M Lewis EJ Wilson KL Greenham AK Bottomley KM Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis Arthritis Rheum 1998, 41:1639-1644 10.1002/1529-0131(199809)41:9<1639::AID- ART1>3.0.CO;2-0 9751097
13. Close DR Matrix metalloproteinase inhibitors in rheumatic diseases Ann Rheum Dis 2001, 60(Suppl 3):iIi62-67 1766680 11890658
14. Hirte H Vergote IB Jeffrey JR Grimshaw RN Coppieters S Schwartz B Tu D Sadura A Brundage M Seymour L A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study Gynecol Oncol 2006, 102:300-308 10.1016/ j.ygyno.2005.12.020 16442153
15. Nemunaitis J Poole C Primrose J Rosemurgy A Malfetano J Brown P Berrington A Cornish A Lynch K Rasmussen H Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies Clin Cancer Res 1998, 4:1101-1109 9607566
16. Rasmussen HS McCann PP Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat Pharmacol Ther 1997, 75:69-75 10.1016/S0163-7258(97)00023-5 9364582
17. Bramhall SR Hallissey MT Whiting J Scholefield J Tierney G Stuart RC Hawkins RE McCulloch P Maughan T Brown PD Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial Br J Cancer 2002, 86:1864-1870 10.1038/sj.bjc.6600310 12085177
18. Tierney GM Griffin NR Stuart RC Kasem H Lynch KP Lury JT Brown PD Millar AW Steele RJ Parsons SL A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer Eur J Cancer 1999, 35:563-568 10.1016/S0959-8049(99)00007-6 10492628
19. Groves MD Puduvalli VK Hess KR Jaeckle KA Peterson P Yung WK Levin VA Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme J Clin Oncol 2002, 20:1383-1388 10.1200/JCO.20.5.1383 11870183
20. Rosemurgy A Harris J Langleben A Casper E Goode S Rasmussen H Marimastat in patients with advanced pancreatic cancer: A dose-finding study Am J Clin Oncol 1999, 22:247-252 10.1097/00000421-199906000-00007 10362330
21. Wojtowicz-Praga S Torri J Johnson M Steen V Marshall J Ness E Dickson R Sale M Rasmussen HS Chiodi TA Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer J Clin Oncol 1998, 16:2150-2156 9626215
22. Hutchinson JW Tierney GM Parsons SL Davis TR Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor J Bone Joint Surg Br 1998, 80:907-908 10.1302/ 0301-620X.80B5.8464 9768907
23. Brown PD Ongoing trials with matrix metalloproteinase inhibitors Expert Opin Invest Drugs 2000, 9:2167-2177 10.1517/13543784.9.9.2167
24. Guingamp C Gegout-Pottie P Philippe L Terlain B Netter P Gillet P Mono-iodoacetate-induced experimental osteoarthritis: A dose-response study of loss of mobility, morphology, and biochemistry Arthritis Rheum 1997, 40:1670-1679 10.1002/art.1780400917 9324022
25. Holmbeck K Bianco P Caterina J Yamada S Kromer M Kuznetsov SA Mankani M Robey PG Poole AR Pidoux I Ward JM MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connective tissue disease due to inadequate collagen turnover Cell 1999, 99:81-92 10.1016/ S0092-8674(00)80064-1 10520996
26. Buckland-Wright JC Macfarlane DG Williams SA Ward RJ Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees Ann Rheum Dis 1995, 54:872-880 1010036 7492235
27. Buckland-Wright JC Macfarlane DG Lynch JA Jasani MK Quantitative microfocal radiography detects changes in OA knee joint space width in subjects in placebo-controlled trial of NSAID therapy J Rheumatol 1995, 22:937-943 8587086
28. Altman R Asch E Bloch D Bole G Borenstein D Brandt K Christy W Cooke TD Greenwald R Hochberg M Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association Arthritis Rheum 1986, 29:1039-1049 10.1002/ art.1780290816 3741515
29. Bellamy N Buchanan WW Goldsmith CH Campbell J Stitt LW Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 1988, 15:1833-1840 3068365
30. Pocock SJ Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 1975, 31:103-115 10.2307/2529712 1100130
31. Clegg DO Reda DJ Harris CL Klein MA O'Dell JR Hooper MM Bradley JD Bingham CO 3rd Weisman MH Jackson CG Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis N Engl J Med 2006, 354:795-808 10.1056/NEJMoa052771 16495392
32. Ernst E Glucosamine and chondroitin sulfate for knee osteoarthritis N Engl J Med 2006, 354:2184-2185 10.1056/NEJMc060829 16707758
33. Altman RD Moskowitz R Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial. Hyalgan Study Group J Rheumatol 1998, 25:2203-2212 9818665
34. Lehmann R Brzosko M Kopsa P Nischik R Kresisse A Thurston H Litschig S Sloan VS Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: A 13-week, randomized, double-blind study vs. placebo and celecoxib Curr Med Res Opin 2005, 21:517-526 10.1185/ 030079905X38196 15899100
35. Wojtowicz-Praga S Clinical potential of matrix metalloprotease inhibitors Drugs R D 1999, 1:117-129 10566004
36. Sher JS Uribe JW Posada A Abnormal findings on magnetic resonance images of asymptomatic shoulders J Bone Joint Surg 1995, 77A:10-15
37. Bissett D O'Byrne KJ von Pawel J Gatzemeier U Price A Nicoloson M Mercier R Mazabel E Penning C Zhang MH Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer J Clin Oncol 2005, 23:842-849 10.1200/JCO.2005.03.170 15681529